control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse ...
Bei Hochrisiko-CLL (TP53-Aberration) war die Prognose etwas schlechter (medianes PFS: 51,9 vs. 20,8 Monate). Ein unmutierter IGVH-Status war ebenfalls mit einem kürzeren medianen PFS as- soziiert und erwies sich, neben der Lymphknotengröße und TP53- Aberrationen, in der ...
Das verschlechtert die LymphomprognoseGerade ältere Patienten mit DLBCL, einem hochmalignen Non-Hodgkin-Lymphom, sind of auch EBV(Epstein-Barr-Virus)-positiv, was die Prognose deutlich verschlechtert. Die erstmals 2003 beschriebene und seit 2008 mit einer vorläufgen WHO-Klassifzierung ...
control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse ...
control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse ...
control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse ...
control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse ...
control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse ...
control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse ...
Bei Hochrisiko-CLL (TP53-Aberration) war die Prognose etwas schlechter (medianes PFS: 51,9 vs. 20,8 Monate). Ein unmutierter IGVH-Status war ebenfalls mit einem kürzeren medianen PFS as- soziiert und erwies sich, neben der Lymphknotengröße und TP53- Aberrationen, in der ...